Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 7  |  Page : 195-200

Uridine diphosphate glucuronide transferase 1A1*28 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer


1 Department of Radiotherapy and Chemotherapy, Zhongnan Hospital of Wuhan University, Wuhan; Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
2 Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
3 Department of Radiotherapy and Chemotherapy, Zhongnan Hospital of Wuhan University, Wuhan, China

Correspondence Address:
Xie Conghua
Department of Radiotherapy and Chemotherapy, Zhongnan Hospital of Wuhan University, Wuhan
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.145871

Rights and Permissions

Objective: The aim was to investigate the association between uridine diphosphate glucuronide transferase 1A1 (UGT1A1) gene promoter region polymorphism and irinotecan-related adverse effects and efficacy on recurrent and refractory small cell lung cancer (SCLC). Materials and Methods: A total of 31 patients with recurrent and refractory SCLC were enrolled in this study from June 2012 to August 2013 and received at least two cycles of single-agent irinotecan chemotherapy. The efficacy and adverse effects of irinotecan were evaluated. DNA was extracted from peripheral blood and direct sequencing method was employed to test UGT1A1*28 polymorphism, thus analyzing the correlation between UGT1A1*28 polymorphism and irinotecan-related side-effects and efficacy. Results: A total of 25 cases (80.6%) were UGT1A1*28 wild-type (TA) 6 /(TA) 6 ; 6 cases (19.4%) were heterozygous mutant (TA) 6 /(TA) 7 , no homozygous mutant genotype (TA) 7 /(TA) 7 was found. The incidences of grade 3/4 neutropenia, diarrhea and thrombocytopenia were 35.5%, 25.8% and 22.6% in all the patients, respectively. The incidence of 3/4 adverse effects in patients with genotype (TA) 6 /(TA) 6 and heterozygous (TA) 6 /(TA) 7 had no statistical difference (P > 0.05 for all). The overall response rate (ORR) was 32.3%. Median progression free survival (PFS) and overall survival (OS) were 4 months and 7.5 months in all patients, respectively. There was no statistical difference in ORR, PFS and OS between genotype (TA) 6 /(TA) 6 patients and heterozygous (TA) 6 /(TA) 7 patients. Conclusion: Irinotecan showed efficacy in patients with recurrent and refractory SCLC; UGT1A1 * 28 polymorphism failed to predict the incidence of serious adverse effects and efficacy of irinotecan.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1396    
    Printed39    
    Emailed1    
    PDF Downloaded107    
    Comments [Add]    

Recommend this journal